IPOR Instituto Peruano de Oncología & Radioterapia
IPOR Instituto Peruano de Oncología & Radioterapia
Av Pablo Carriquiry 115, San Isidro 15036, Peru
Select an option
I am a doctor
I am a sponsor
Open studies
Breast Cancer
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) - TroFuse-011 - Merck Sharp & Dohme LLCSee more
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) - MK-2870-032 - Merck Sharp & Dohme LLCSee more
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) - HERTHENA-Breast04 - Merck Sharp & Dohme LLCSee more
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) - OMAHA-015 - Merck Sharp & Dohme LLCSee more
Endometrial Cancer
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) - TroFuse-033 - Merck Sharp & Dohme LLCSee more
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) - OMAHA-015 - Merck Sharp & Dohme LLCSee more
Prostate cancer
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) - IDeate-Prostate01 - Merck Sharp & Dohme LLCSee more
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) - IDeate-Prostate01 - Merck Sharp & Dohme LLCSee more
Ovarian cancer
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) - TroFuse-022 - Merck Sharp & Dohme LLCSee more
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) - OMAHA-015 - Merck Sharp & Dohme LLCSee more
Lung cancer
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) - MK-2870-019 - Merck Sharp & Dohme LLCSee more
Bladder Cancer
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) - INTerpath-011 - Merck Sharp & Dohme LLCSee more
Solid tumors
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) - OMAHA-015 - Merck Sharp & Dohme LLCSee more
